Compare Abbott Laboratories (ABT) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Peloton Interactive Inc — how do they compare? Abbott Laboratories trades at $111.03 (market cap $187.95B), while Peloton Interactive Inc trades at $5.47 (market cap $2.46B). The key difference: Abbott Laboratories is far larger — about 76.4× Peloton Interactive Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| ABT | PTON | |
|---|---|---|
Market Cap | $187.95B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $9.00 |
52-Week Low | $82.57 | $3.71 |
Enterprise Value | $214.96B | $2.96B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Peloton Interactive (PTON) trades at $5.45, down 1.09% on the day, reflecting ongoing investor caution despite achieving its first full-year net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals highlight a challenging revenue decline to $2.4B in 2026, though net income turned positive at $63M. Analyst sentiment is mixed, with a 'Hold' consensus amid concerns over subscriber losses and a muted 2027 outlook.
The outlook remains cautious; profitability improvements and cost control offer a foundation, but persistent revenue declines and high debt levels pose significant risks. Investors should weigh the company's turnaround progress against competitive pressures and execution challenges in a saturated fitness market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
